Recurrent Uterine Carcinosarcoma
1 clinical trials · Condition
◉ Watch Recurrent Uterine Carcinosarcoma
| Record | Firm | Date |
|---|---|---|
| Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT03552471) | Ohio State University Comprehensive Cancer Center | 2018-07-12 |
Track Recurrent Uterine Carcinosarcoma automatically
Every clearance here is in the API, with alerts when new ones post.